Crystallization of Huntingtin Exon 1 Using Microgravity (CASIS PCG HDPCG-1) - 11.25.15
The Crystallization of Huntingtin Exon 1 Using Microgravity (CASIS PCG HDPCG-1) investigation focuses on the crystallization of huntingtin, a protein associated with Huntington’s disease. Crystallization is crucial for the development of new drugs to treat this degenerative brain disorder, which is caused by an inherited mutation in the huntingtin gene. But the huntingtin protein has evaded crystallization for more than a decade. Crystallizing it would be an important milestone in the field of macromolecular crystallography as well as a step toward developing a treatment for this ultimately fatal disease.
Science Results for Everyone
Information Pending Experiment Details
OpNom: Handheld HDCPG
Pamela Bjorkman, Ph.D., California Institute of Technology, Pasadena, CA, United States
University of Alabama at Birmingham, Birmingham, AL, United States
Sponsoring Space Agency
National Aeronautics and Space Administration (NASA)
National Laboratory (NL)
ISS Expedition Duration 1
March 2014 - September 2014
Previous ISS Missions
Huntington’s disease is a fatal neurodegenerative disorder with no known cure. Crystallization of huntingtin, which has evaded crystallization for more than a decade, would be an important milestone in the field of macromolecular crystallography. The crystallization of huntingtin is needed because it is crucial for development of new drugs for the treatment of Huntington’s disease and other related disorders.
Researchers plan to grow crystals of medically relevant proteins to accurately determine their shape to fit new drugs. The proteins chosen are proving extremely difficult to crystalize on Earth and it is believed that zero-gravity will allow the crystals to grow. This investigation crystallizes huntingtin exon 1 using the unique microgravity environment to increase the crystal quality and size compared to protein crystals grown on Earth.
Because huntingtin is part of a larger class of amyloidogenic proteins whose crystal structures have also never been solved, the crystallization of huntingtin would be a scientific breakthrough in crystallization of these difficult proteins. Commercial impact of crystallization of huntingtin includes potential development of pharmaceutical agents that specifically bind to the structure of mutant huntingtin.
In microgravity, the elimination of sedimentation and convection produces a highly unique environment for space-based experiments such as protein crystallization. The human body contains over 100,000 proteins that play important roles in the everyday function of the body such as the formation of major components of muscle and skin, and how the body fights diseases. In order to fully understand the function of proteins, three-dimensional structural information becomes necessary. The structure of individual proteins can be studied with the growth of high quality crystals in which the molecules of the protein are arranged in a regular, repeating pattern. In order to produce high-quality crystals of a protein, it must be reasonably pure with respect to other contaminating proteins, it must be homogeneous and it's three-dimensional conformation relatively stable. Crystallization occurs in aqueous solution when purified protein molecules are coaxed to slowly self-associate, through relatively weak interactions such as ionic or hydrogen bonds. Individual protein molecules align themselves in a repeating series of "unit cells" by adopting a consistent orientation that eventually forms a crystal with sharp facets. Protein crystallization serves as the basis for X-ray crystallography, wherein a crystallized protein is used to determine the protein’s three-dimensional structure via x-ray diffraction. This investigation aims to successfully crystallize the first complete structure of huntingtin exon 1 using microgravity, alone and in complex with binding proteins to stabilize the pathogenic polyglutamine regions of huntingtin. A structure of huntingtin would address a critical problem in engineering new therapeutics to treat or prevent Huntington’s disease- the absence of a complete X-ray crystal structure of the pathologic region of huntingtin. Crystallization is performed using the Vapor Diffusion technique inside the Handheld HDPCG. This technique is also known as the hanging drop method of crystal growth. This process entails a droplet containing purified protein, buffer, and precipitant being allowed to equilibrate with a larger reservoir containing similar buffers and precipitants in higher concentrations. Initially, the droplet of protein solution contains an insufficient concentration of precipitant for crystallization, but as water vaporizes from the drop and transfers to the reservoir, the precipitant concentration increases to a level optimal for crystallization.
In general, crystals grown in microgravity are able to reach much larger sizes and more perfect forms than those grown on Earth, because the effects of gravity are removed. Crystallizing proteins allows scientists to determine how they are structured, and thereby how a new drug might interact with them. Existing processes have been unable to crystallize proteins that are prone to clumping together, including huntingtin and the amyloid-beta protein involved in Alzheimer’s disease. This investigation could yield a new area of space-based research in protein crystallography, especially for proteins whose structure or size makes them difficult or impossible to crystallize on Earth. In addition, if this investigation demonstrates that several important proteins only crystallize in microgravity, a new multi-billion-dollar market could emerge for development of highly effective and specific treatments.
Using a three-dimensional crystal, scientists may be able to identify a potential drug treatment for Huntington’s disease. Scientists aim to identify specific sections of the protein that might interact with other compounds. This could produce a new targeted drug that works efficiently with few side effects, improving the quality of life for patients with Huntington’s disease. Additionally, new insight into the physics of crystal formation in microgravity could lead to new approaches in crystallography on Earth, including for several other medically relevant proteins.
- Preflight late loading (~L-24 hours) and postflight early access (R+48) required
- Temperature Controlled environment (+4 Deg C +/- 2 Deg C) for turnover, launch, on-orbit and return.
Minimal crew time: ~ 60 minutes
- 30 minutes for access from cold stowage and sample activation (2 blocks)
- 30 minutes at end of mission to deactivate (2 Blocks) and stow in Cold stowage for return.
- Quiescent microgravity environment during the sample activated period.
- Cold Stowage unpacking
- HH HDPCG Activation
- HH HDPCG Deactivation
Cold Stowage packing
Decadal Survey Recommendations
Information Pending^ back to top
Information Pending^ back to top
NASA Image: ISS041E078028 - NASA astronaut Reid Wiseman retrieving Ambient Handheld High Density Protein Crystal Growth (HDPCG) Unit
+ View Larger Image
NASA Image: ISS041E078032 - NASA astronaut Reid Wiseman retrieving Ambient Handheld High Density Protein Crystal Growth (HDPCG) Unit
+ View Larger Image
NASA Image: ISS041E078040 - NASA astronaut Reid Wiseman retrieving Ambient Handheld High Density Protein Crystal Growth (HDPCG) Unit.
+ View Larger Image